Selective SIRT2 inhibitors such as SG3 (IC50 = 1.95 μM) and isobavachalcone (IC50 = 0.84 μM) (Figure 1) demonstrated strong antitumor activity by inducing α-tubulin hyperacetylation, suppressing the STAT3/c-Myc and Snail/MMP pathways, resulting in apoptosis and S-phase arrest in TNBC models, with significant tumor size reduction [128,129]. Here, SIRT2 is linked to neoplasm.